Alzheimer’s Disease - Pipeline Assessment and Market Forecasts to 2017

Alzheimer’s Disease - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Alzheimer’s Disease - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Alzheimer’s disease market. The report identifies the key trends shaping and driving the global Alzheimer’s disease market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Alzheimer’s disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData has estimated the global Alzheimer’s disease therapeutics market to be valued at $7.1 billion in 2009. It is expected to decline to $5.2 billion with a Compound Annual Growth Rate (CAGR) of (4%) by 2017. The market structure is projected to change in the near future following the patent expiry of the leading drugs in next 2-3 years. Aricept patent expires in November 2010, Namenda’s (Forest) patent is set to expire in April 2015. There is a high unmet need in the current Alzheimer’s disease market in terms of both safety and efficacy profile

Scope

The report provides information on the key drivers and challenges of the Alzheimer’s disease market. Its scope includes:

• Annualized global Alzheimer’s disease market revenues data from 2001 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as of cholinesterase inhibitors, N-methyl D-aspartate, serotonin receptor antagonists, immunotherapy, gamma secretase inhibitors and beta secretase inhibitors.
• Analysis of the current and future competition in the global Alzheimer’s disease market. Key market players covered are Pfizer, AstraZeneca, Baxter Healthcare, Elan and Medivation.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Alzheimer’s disease therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Alzheimer’s disease market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Alzheimer’s disease market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Alzheimer’s disease market landscape? – Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 ALZHEIMER’S DISEASE THERAPEUTICS : INTRODUCTION

2.1 GlobalData Report Guidance

3 ALZHEIMER’S DISEASE THERAPEUTICS: MARKET CHARACTERIZATION

3.1 Overview
3.2 Alzheimer’s Disease Therapeutics Market Size
3.3 Alzheimer’s Disease Therapeutics Market Forecast and CAGR
3.4 Drivers and Barriers for the Alzheimer’s Disease Therapeutics
  3.4.1 Drivers for the Alzheimer’s Disease Therapeutics
  3.4.2 Barriers for the Alzheimer’s Disease Therapeutics Market
3.5 Opportunity and Unmet Need
3.6 Key Takeaway

4 ALZHEIMER’S DISEASE THERAPEUTICS: COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Alzheimer’s Disease Therapeutics
  4.3.1 Aricept (donepezil hydrochloride)
  4.3.2 Exelon (rivastigmine titrate)
  4.3.3 Namenda (memantine hydrochloride)
4.4 Other Marketed Products for Alzheimer’s Disease Therapeutics
  4.4.1 Cognex
  4.4.2 Razadyne (galantamine hydrobromide extended release capsules)
4.5 Key Takeaway

5 ALZHEIMER’S DISEASE THERAPEUTICS: PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
  5.2.1 Technology Trends Analytical Framework
5.3 Alzheimer’s Disease Therapeutics-Promising Drugs Under Clinical Development
5.4 Molecular Profile for the Promising Drugs under Clinical Development
  5.4.1 Bapineuzumab
  5.4.2 Gammagard
  5.4.3 Dimebon
  5.4.4 Rember (Trx0014) (methylthionium chloride)
5.5 Alzheimer’s Disease Therapeutics – Clinical Pipeline by Mechanism of Action
5.6 Alzheimer’s Disease Therapeutics Pipeline – Pipeline by Clinical Phases of Development
  5.6.1 Alzheimer’s Disease Therapeutics – Regulatory and Phase III Clinical Pipeline
  5.6.2 Alzheimer’s Disease Therapeutics – Phase II Clinical Pipeline
  5.6.3 Alzheimer’s Disease Therapeutics – Phase I Clinical Pipeline
  5.6.4 Alzheimer’s Disease Therapeutics – Preclinical Pipeline
  5.6.5 Alzheimer’s Disease Therapeutics – Discovery Pipeline
5.7 Discontinued / Suspended Drugs for Alzheimer’s disease
5.8 Key Takeaway

6 ALZHEIMER’S DISEASE THERAPEUTICS: IMPLICATIONS FOR THE FUTURE MARKET COMPETITION

7 ALZHEIMER’S DISEASE THERAPEUTICS: FUTURE PLAYERS IN THE MARKET

7.1 Introduction
7.2 AstraZeneca
  7.2.1 Overview
  7.2.2 Central Nervous System Portfolio
  7.2.3 Alzheimer’s disease Portfolio
7.3 Elan
  7.3.1 Overview
  7.3.2 CNS Portfolio
  7.3.3 Alzheimer’s Disease Product Portfolio
7.4 Wyeth (Pfizer)
  7.4.1 Overview
  7.4.2 CNS Portfolio
  7.4.3 Alzheimer’s Disease Product Portfolio
7.5 Medivation
  7.5.1 Overview
  7.5.2 CNS Portfolio
  7.5.3 Alzheimer’s Disease Product Portfolio
7.6 Baxter Healthcare
  7.6.1 Overview
  7.6.2 CNS Portfolio
  7.6.3 Alzheimer’s Disease Product Portfolio

8 ALZHEIMER’S DISEASE THERAPEUTICS MARKET : APPENDIX

8.1 Market Definitions
8.2 Scope of Pipeline Research
8.3 Abbreviations
8.4 Research Methodology
  8.4.1 Coverage
  8.4.2 Secondary Research
  8.4.3 Forecasting
  8.4.4 Primary Research
  8.4.5 Expert Panel validation
8.5 Contact Us
8.6 Disclaimer
8.7 Sources

LIST OF TABLES

Table 1: Alzheimer’s Disease Therapeutics,Global ($bn)2001-2009
Table 2: Alzheimer’s Disease Therapeutics, Global, Market Forecast ($bn), 2009-2017
Table 3: Major marketed products comparison in Alzheimer’s Disease, 2010
Table 4: Alzheimer’s Disease Therapeutics – Most Promising Drugs Under Clinical Development, 2010
Table 5: Alzheimer’s Disease Therapeutics – Regulatory and Phase III Clinical Pipeline, 2010
Table 6: Alzheimer’s Disease Therapeutics – Phase II Clinical Pipeline, 2010
Table 7: Alzheimer’s Disease Therapeutics – Phase I Clinical Pipeline, 2010
Table 8: Alzheimer’s Disease Therapeutics – Preclinical Pipeline, 2010
Table 9: Alzheimer’s Disease Therapeutics – Discovery Pipeline, 2010
Table 10: List of Discontinued Drugs for Alzheimer’s Disease, 2010
Table 11: Alzheimer’s Disease Therapeutics – List of Other Discontinued Drugs in Pipeline, 2010
Table 12: AstraZeneca – CNS Marketed Products, 2010
Table 13: AstraZeneca – CNS Pipeline Products, 2010
Table 14: Elan – CNS Marketed Products, 2010
Table 15: Elan– CNS Pipeline Products, 2010
Table 16: Wyeth (Pfizer) – CNS Marketed Products, 2010
Table 17: Wyeth (Pfizer) – CNS Pipeline Products, 2010
Table 18: Medivation – CNS Pipeline Products, 2010
Table 19: Baxter Healthcare – CNS Marketed Products, 2010
Table 20: Baxter Healthcare – CNS Pipeline Products, 2010

LIST OF FIGURES

Figure 1: Alzheimer’s Disease Therapeutics , Revenues, ($bn)2001-2009
Figure 2: Alzheimer’s Disease Therapeutics, Global, Market Forecast ($bn), 2009-2017
Figure 3: Opportunity and Unmet Need in the Alzheimer’s Disease Therapeutics, 2010
Figure 4: Srategic Competitor Assessment of the Major Marketed Products for Alzheimer’s Disease, 2010
Figure 5: Technology Trends Analytic Framework of Alzheimer’s Disease Therapeutics, 2010
Figure 6: Alzheimer’s Disease Therapeutics – Clinical Pipeline by Mechanism of Action, 2010
Figure 7: Alzheimer’s Disease Therapeutics Pipeline by Phase of Clinical Development, 2010
Figure 8: Implications for Future Market Competition in the Alzheimer’s Disease Therapeutics Market,2010
Figure 9: Alzheimer’s Disease Therapeutics.– Pipeline by Company, 2010
Figure 10: GlobalData Market Forecasting Model

COMPANIES MENTIONED

AstraZeneca
Elan
Wyeth (Pfizer)
Medivation
Baxter Healthcare
Skip to top